Experiment: 6OKX

SOLUTION NMR

NMR Experiment
Experiment	Type	Sample Contents	Solvent	Ionic Strength	pH	Pressure	Temperature (K)	Spectrometer
1	2D 1H-15N HSQC	0.5 mM [U-99% 13C; U-99% 15N] VEK50RH1/AA, 2 ug/mL DSS, 1 ug/mL DTT, 20 mM [U-2H] Bis-Tris-d19	93% H2O/7% D2O	20 mM	6.8	1 atm	298	Bruker AVANCE II 800
2	2D NOESY	0.5 mM [U-99% 13C; U-99% 15N] VEK50RH1/AA, 2 ug/mL DSS, 1 ug/mL DTT, 20 mM [U-2H] Bis-Tris-d19	93% H2O/7% D2O	20 mM	6.8	1 atm	298	Bruker AVANCE II 800
3	3D CBCA(CO)NH	0.5 mM [U-99% 13C; U-99% 15N] VEK50RH1/AA, 2 ug/mL DSS, 1 ug/mL DTT, 20 mM [U-2H] Bis-Tris-d19	93% H2O/7% D2O	20 mM	6.8	1 atm	298	Bruker AVANCE II 800
4	3D C(CO)NH	0.5 mM [U-99% 13C; U-99% 15N] VEK50RH1/AA, 2 ug/mL DSS, 1 ug/mL DTT, 20 mM [U-2H] Bis-Tris-d19	93% H2O/7% D2O	20 mM	6.8	1 atm	298	Bruker AVANCE II 800
5	3D HNCO	0.5 mM [U-99% 13C; U-99% 15N] VEK50RH1/AA, 2 ug/mL DSS, 1 ug/mL DTT, 20 mM [U-2H] Bis-Tris-d19	93% H2O/7% D2O	20 mM	6.8	1 atm	298	Bruker AVANCE II 800
6	3D HNCA	0.5 mM [U-99% 13C; U-99% 15N] VEK50RH1/AA, 2 ug/mL DSS, 1 ug/mL DTT, 20 mM [U-2H] Bis-Tris-d19	93% H2O/7% D2O	20 mM	6.8	1 atm	298	Bruker AVANCE II 800
8	3D HNCACB	0.5 mM [U-99% 13C; U-99% 15N] VEK50RH1/AA, 2 ug/mL DSS, 1 ug/mL DTT, 20 mM [U-2H] Bis-Tris-d19	93% H2O/7% D2O	20 mM	6.8	1 atm	298	Bruker AVANCE II 800

NMR Spectrometer Information
Spectrometer	Manufacturer	Model	Field Strength
1	Bruker	AVANCE II	800

NMR Refinement
Method	Details	Software
simulated annealing		X-PLOR NIH

NMR Ensemble Information
Conformer Selection Criteria	structures with the least restraint violations
Conformers Calculated Total Number	200
Conformers Submitted Total Number	20
Representative Model	1 (fewest violations)

Computation: NMR Software
#	Classification	Version	Software Name	Author
1	collection	TopSpin		Bruker Biospin
2	data analysis	Sparky		Goddard
3	chemical shift assignment	Sparky		Goddard
4	structure calculation	CS-ROSETTA		Shen, Vernon, Baker and Bax
5	refinement	X-PLOR NIH		Schwieters, Kuszewski, Tjandra and Clore
6	structure calculation	X-PLOR NIH		Schwieters, Kuszewski, Tjandra and Clore

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.